A new mouse model of metabolic syndrome and associated complications

Yun Wang, Yue Zheng, Patsy M Nishina and Jürgen K Naggert

The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 04609, USA

(Correspondence should be addressed to J K Naggert; Email: juergen.naggert@jax.org)

Abstract

Metabolic syndrome (MS) encompasses a clustering of risk factors for cardiovascular disease, including obesity, insulin resistance, and dyslipidemia. We characterized a new mouse model carrying a dominant mutation, C57BL/6J-*Nmfl5*/+ (B6-*Nmfl5*/+), which develops additional complications of MS such as adipose tissue inflammation and cardiomyopathy. A backcross was used to genetically map the *Nmfl5* locus. Mice were examined in the comprehensive laboratory animal monitoring system, and dual energy X-ray absorptiometry and blood chemistry analyses were performed. Hypothalamic LEPR, SOCS1, and STAT3 phosphorylation were examined. Cardiac function was assessed by echo- and electrocardiography. Adipose tissue inflammation was characterized by *in situ* hybridization and measurement of Jun kinase activity. The *Nmfl5* locus mapped to distal mouse chromosome 5 with an LOD (logarithm of odds) score of 13.8. *Nmfl5* mice developed

obesity by 12 weeks of age. Plasma leptin levels were significantly elevated in pre-obese *Nmfl5* mice at 8 weeks of age and an attenuated STAT3 phosphorylation in the hypothalamus suggests a primary leptin resistance. Adipose tissue from *Nmfl5* mice showed a remarkable degree of inflammation and macrophage infiltration as indicated by expression of the F4/80 marker and increased phosphorylation of JUN N-terminal kinase 1/2. Lipidosis was observed in tubular epithelial cells and glomeruli of the kidney. *Nmfl5* mice demonstrate both histological and pathophysiological evidence of cardiomyopathy. The *Nmfl5* mouse model provides a new entry point into pathways mediating leptin resistance and obesity. It is one of few models that combine many aspects of MS and can be useful for testing new therapeutic approaches for combating obesity complications, particularly cardiomyopathy.

Journal of Endocrinology (2009) **202**, 17–28

Introduction

The term ‘metabolic syndrome’ (MS) is used to describe the simultaneous occurrence of obesity, insulin resistance, dyslipidemia, and hypertension. This syndrome is emerging as one of the major medical and public health problems both in the United States and worldwide. Currently, ~25% of North Americans are thought to be affected by MS (Eckel *et al.* 2005, Tiffin *et al.* 2008). As the epidemic of obesity shows no signs of reversing, the prevalence of the MS is likely to rise in the future (Ford *et al.* 2002). Despite its high prevalence, the pathogenesis of MS is not completely understood (Olufadi & Byrne 2008).

Although existing mouse models have been fundamental to advancing our knowledge of the basis of obesity, type 2 diabetes, and dyslipidemia, we are still at an early stage in understanding MS as a complex disorder. Traditionally, leptin-deficient (*Lep^{ob}*) and leptin receptor-deficient (*Leprd*) mice, representing extremes of obesity syndromes, have been used for studies of obesity, adipocyte dysfunction, and insulin resistance (Coleman 1985). More recently, diet-induced and polygenic models have become increasingly used, but pose

challenges for the identification of the underlying genetic causes of their phenotypes. Therefore, there remains a need for new monogenic animal models that recapitulate the complexity of the human MS. The study of two aspects of MS, in particular, would benefit from the availability of new models, adipose tissue inflammation, and obesity-associated cardiomyopathy.

Obesity-induced inflammation is characterized in part by the infiltration of macrophages and other immune cells into white adipose tissue, and has been observed in both rodents and humans (Wellen & Hotamisligil 2003, Cencello & Clement 2006). However, the molecular reasons for adipose tissue inflammation and macrophage infiltration in obesity are not fully understood (Heilbronn & Campbell 2008).

Most reports of cardiac dysfunction have used type 1 diabetes-induced (T1D) models (Tomlinson *et al.* 1992, Yu *et al.* 1994), whose usefulness with respect to MS may be limited to hyperglycemia. Non-insulin-dependent (type 2) diabetes is a prevalent disease that results in an increase in cardiovascular complications (Grundy *et al.* 1999) among them a specific cardiomyopathy, characterized by ventricular

dysfunction in the absence of atherosclerotic coronary heart disease or hypertension (Fein 1990).

The *Nmf15* mouse model carries a dominant mutation generated through ENU mutagenesis. As reported herein, mice heterozygous for the *Nmf15* mutation phenotypically develop late onset obesity. In addition to obesity, dyslipidemia, and adipose tissue inflammation, B6-*Nmf15*/+ mice are also characterized by hyperinsulinemia without significant hyperglycemia. Hyperleptinemia is already found in young pre-obese mice (7–8 weeks of age) fed standard chow. In addition, B6-*Nmf15*/+ mice develop lipid deposits in liver and kidney, and a progressive dilated cardiomyopathy (DCM). The unique combination of features in *Nmf15* mice offers a useful paradigm for understanding human hyperleptinemic MS associated with obesity and cardiac failure. Since the MS in *Nmf15* mice is a single gene trait, the underlying genetic cause is more easily tractable and will lead to the identification of a critical component in the disease pathway leading to MS. *Nmf15* mice also represent a valuable new tool for testing new therapies.

Materials and Methods

Mice

Breeding pairs of B6-*Nmf15*/+ mice were obtained from the Neuro Mutagenesis Facility at The Jackson Laboratory. Colonies of *Nmf15* mice were maintained on an NIH mouse/rat diet with 4% fat (#5K54, PMI Feeds Inc., St Louis, MO, USA), fed *ad libitum* with free access to water (HCl acidified, pH 2.8–3.2) under controlled temperature and humidity with a 12 h light:12 h darkness cycle (lights on from 0600 to 1800 h). All animal studies were performed with the approval of The Jackson Laboratory Animal Care and Use Committee (protocol no. 99089).

Transfer of the *Nmf15* mutation onto a non-mutagenized C57BL/6J background

To reduce the mutation load that is present in mutant mice obtained from an ENU mutagenesis screen, the mutant C57BL/6J-*Nmf15*/+ (B6-*Nmf15*/+) mice were backcrossed to non-mutagenized C57BL/6J (B6) mice. To characterize the dominant MS mutation, B6-*Nmf15*/+ mice beyond backcross (BC) generation 7 (>N7) were used.

Inheritance of *Nmf15*

An obese mouse (*Nmf15*) was observed in the first generation (G1) of an ENU mutagenesis screen. Breeding of the founder mouse to wt B6 confirmed that the obesity phenotype was inherited as a dominant trait. Despite several attempts either through intercrossing of B6.AKR-*Nmf15*/+ mice or by ovarian transplant, no mice homozygous for the *Nmf15* mutation were obtained.

Chromosomal mapping of the *Nmf15* mutation

We conducted a genome-wide mapping study for obesity in B6-*Nmf15*/+ mice by outcrossing to the inbred AKR/J strain mice and backcrossing male and female (AKR×B6-*Nmf15*/+) F1 mice to AKR/J. A cohort of BC mice from the cross was genotyped and phenotyped for body weight at 12 weeks of age. Thirty-five BC animals were genotyped using 57 evenly spaced microsatellite markers for a genome scan to locate the *Nmf15* mutation. The location was confirmed and the map position refined in a second cohort of 239 BC animals genotyped using 11 microsatellite markers on chromosome 5. Isolation of genomic DNA and genotyping was described previously (Wang *et al.* 1997).

Quantitative trait locus (QTL) mapping and statistics

QTL analysis and genome scans were performed using the scanone and bayesint functions of the R/qtl package (<http://research.jax.org/faculty/churchill/software/Jqtl/index.html>) as described previously (Broman *et al.* 2003). Significance of QTL logarithm of odds (LOD) scores was assessed using 1000 permutations of the phenotypic data (Churchill & Doerge 1994). A Bayesian credible interval for chromosome 5 was computed and reported as confidence interval.

Comprehensive laboratory animal monitoring system (CLAMS)

The CLAMS (Columbus Instruments, Columbus, OH, USA) is a set of live-in cages for automated, non-invasive, and simultaneous monitoring of horizontal and vertical activity, feeding and drinking, oxygen consumption, and CO₂ production. Seven- to eight-week-old B6-*Nmf15*/+ mice and controls were individually placed in CLAMS cages and monitored over a 5-day period. Food and water consumption were measured directly as accumulated data. The hourly file displays all measurements for each parameter: volume of oxygen consumed, ml/kg per h (VO₂), volume of carbon dioxide produced, ml/kg per h (VCO₂), respiratory exchange ratio, heat (kcal/h), accumulated food (g), accumulated drink (g), XY total activity (all horizontal beam breaks in counts), XY ambulatory activity (minimum three different, consecutive horizontal beam breaks in counts), and Z activity (all vertical beam breaks in counts). The data were recorded during the 30-s sampling period.

Dual energy X-ray absorptiometry

The LUNAR PIXImus mouse densitometer (GE Lunar, Madison, WI, USA) is a dual-energy supply X-ray machine for measuring skeletal and soft tissue mass, enabling assessment of skeletal and body composition in mice. Mice scanned alive were anesthetized with 2% tribromoethanol. Mice were individually placed on plastic trays, which were then placed onto the exposure platform of the PIXImus machine to measure body composition.

Metabolic parameters and glucose homeostasis

Blood was drawn ~4 h after the onset of light from the retro-orbital plexus via heparinized capillary tubes and plasma was obtained by centrifugation (1200 g) at 4 °C. Measurements of plasma glucose, total-cholesterol, high density lipoprotein (HDL)- and low density lipoprotein (LDL)-cholesterol, triglycerides, free fatty acids, alkaline phosphatase, pancreatic lipase, T₄, and calcium were performed using a Beckman Coulter Synchron CX5 Delta chemistry analyzer (Beckman Coulter, Inc., Diagnostic Division, Brea, CA, USA). The plasma hormone levels of leptin, adiponectin, resistin, and insulin were measured by ELISA (Linco Research, St Charles, MO, USA).

For the glucose tolerance test, mice were fasted for 16 h, and were given i.p. injection with 0.5 g/kg dosage (50% solution of D-50 dextrose). Blood glucose levels were measured using OneTouch Ultra Blood Glucose Monitoring system (LifeScan Inc., Milpitas, CA, USA) at 15, 30, 60, 120, and 180 min after glucose administration. For insulin tolerance tests (ITT), mice were fasted for up to 4 h and the insulin diluted in 0.9% saline was administered by i.p. injection (1 U/kg). Blood glucose levels were monitored as above immediately prior to injection T₀, and at 30, 60, 90, and 120 min after injection. These data were expressed as % T₀ blood glucose levels versus time.

Real-time quantitative PCR

Real-time PCR assays were performed as previously described (Wang *et al.* 2006) on an ABI PRISM 7500 SDS instrument (Applied Biosystems). Samples were analyzed in triplicate in three independent runs. To quantify the gene expression profiles, we used the comparative threshold cycle method. PCR amplified 150–180 bp fragments of cDNA, IL-6 (F: GCTAAGGACCAAGACCATCCAAT, R: CTTGAACATAAGACAGATAGGACCAA), MCP-1 (F: CTGCATCTGCCCTAAGGTCTT, R: GTGCTTGAGG-TGGTTGTGGAA), PAI-1 (F: GGCCAAAGGAAAAA-GCACTGT, R: GGGCCACCATTGTGATCTGT-CTA), and TNF- α (F: GACGTGGAAGTGGCAGAAGAG, R: GCCACAAGCAGGAATGAGAAG).

Histopathology of the heart, liver, and kidney

Tissues of B6-*Nmf15*/+ mice and age-matched littermate controls were harvested, washed with ice-cold PBS, and either fixed in 10% formalin or in Streck's tissue fixative (Streck Laboratories, Omaha, NE, USA) overnight and were finally paraffin embedded. Histochemical analysis was carried out on 4- μ m-thick sections using hematoxylin and eosin (HE) and trichrome staining.

Oil-Red-O staining

Frozen 10- μ m-thickness cryosections from liver and kidney were fixed with 10% formaldehyde. Approximately, 5 min

Figure 1 Mapping of the *Nmf15* locus. Distribution of 12 week body weights from a (AKR/J $\times$ B6-*Nmf15*/+) F1 $\times$ AKR/J backcross (A). Genome scan and chromosomal mapping. A suggestive map location for *Nmf15* was found on chromosome 5 (B). The location was confirmed in a second backcross ($n=239$) with a peak LOD score of 13.8 on distal chromosome 5. The 95% confidence interval was between 44 and 60 cM (C). (Figure A was generated by StatView 4.5. 1) The S.D. is indicated by the bar above the box; the S.E.M. is represented by the bar under the box. 2) The circles above and below the box represent the values of BW from animals that are higher than group S.D. and lower than group S.E.M. respectively. 3) The line inside of the box is the mean value. 4) The box is representing the range of total animals' body weight distribution.

after the fixation, Oil-Red-O stain (Oil-Red-O stock solution saturated in isopropanol (Rowley Biochemical Institute, cat: So-385) was used for 10 min to stain for lipid accumulation. After rinsing with distilled water, the slides

were stained in Mayers Hematoxylin for 5 min, washed with distilled water for 15 min, and mounted with aqueous solution. Sections were visualized at a magnification of $\times 40$ and $\times 100$.

Echocardiography

Vevo 770 High-Frequency Ultrasound equipment (Visualsonics, Toronto, Ontario, Canada) was used. Animals were anesthetized with 5% isoflurane at 0.8 l/min and maintained anesthetized with 1–1.5% isoflurane at 0.8 l/min. Animals were allowed to recover under a heat lamp upon completion of imaging.

Electrocardiogram

The animals were restrained in a Murine ECG Restraint from QRS Phenotyping Inc. (Calgary, Alberta, Canada), and the signal acquisition used a PowerLab system from AD Instruments (Golden, CO, USA). To perform an electrocardiogram (ECG) on anesthetized mice, the animals were anesthetized with 5% isoflurane at 1 l/min and maintained at 1.5% at 0.8 l/min. Body temperature was maintained with an overhead heat lamp. A three-lead configuration was used to acquire the electrical signals.

Measurement of blood pressure

The CODA6 non-invasive blood pressure (BP) system (Kent Scientific, Torrington, CT, USA) was used to measure BP parameters: systolic, diastolic, mean, heart pulse rate, tail blood volume, and tail blood flow. Mice were placed in a clear plastic tube with nose cone and tail hole pieces secured at either end. These tubes were then placed on a platform heated to $\sim 35^\circ\text{C}$ and the mice were allowed to warm to platform temperature for 5–15 min prior to the experiment. Mice were habituated to the procedure with 10–30 preliminary cycles; thereafter, 30 data measurements were recorded for each mouse. Measurements were performed at the same time each day, generally between 0700 and 1100 h in a sound-barrier room.

In situ hybridization

Adipose tissue was fixed in 4% paraformaldehyde PBS for 18 h, dehydrated, and embedded in paraffin. A minimum of three samples from three different animals in each group were used for this experiment. Sections of 6- μm thickness were cut and mounted on slides pre-treated with poly L-lysine (Sigma). The sense and antisense riboprobes were generated from plasmids containing cDNA fragments of F4/80 labeled by digoxigenin.

Measurement of JUN N-terminal kinase activation

The phosphorylation status at threonine 183 and tyrosine 185 of JUN N-terminal kinase (JNK) 1/2 was assayed using a commercial antibody beadkit for phospho-JNK1/2 [pTpY 183/185] (Cat. LHO0081, Biosource, Camarillo, CA, USA).

Figure 2 *B6-Nmf15/+* mice are obese and have decreased activity levels and reduced oxygen consumption. Longitudinal changes of body weight of *B6-Nmf15/+* mice from 4 to 20 weeks of age (A). Open and filled symbols represent *B6-+/+* and *B6-Nmf15/+* mice respectively. Squares and circles represent male and female respectively ($n=50$ –100). DEXA analysis of body composition, body fat content, and lean body mass from both *B6-Nmf15/+* and control mice ($n=8$) at 12–14 weeks of age (B and C). Daily pattern of activity (D), food intake (E), and oxygen consumption (F) at 8 weeks of age ($n=8$). * $P<0.05$, ** $P<0.01$ for *B6-Nmf15/+* samples versus the respective *B6-+/+* samples.

Figure 3 B6-*Nmfl5*/+ mice are hyperleptinemic and show reduced leptin sensitivity in the hypothalamus. Longitudinal measurement of leptin (A) and adiponectin (B), and reduced leptin sensitivity in hypothalamus at 12-weeks of age (C, D, and E). Cohorts of $n=20$ (A and B) and $n=4$ (C) were used. * $P<0.05$, ** $P<0.01$ for B6-*Nmfl5*/+ samples versus the respective B6-+/+ samples.

Western-blot analysis

After an overnight fast, mice were injected with saline or leptin i.p. (3 mg/kg). Five hours later, mice were anesthetized before decapitation, and the brain was rapidly removed (Martin *et al.* 2006). Using a cooled mouse brain matrix with 1-mm section dividers, the hypothalamus was dissected as described previously (Munzberg *et al.* 2004, Martin *et al.* 2006). Hypothalamus tissue lysates were prepared as described previously (Martin *et al.* 2006). Phosphorylation of STAT3 in the hypothalamus was determined by western-blot analysis of 4–12% SDS-acrylamide gels using an antibody against phosphotyrosine705 (Cell Signaling, Danvers, MA, USA) of STAT3 (Cell Signaling). The measurements of phosphorylation of JKN1/2 in adipose tissue and LEPR and

SOCS1 in the hypothalamus were carried out by western-blot analysis of 10% SDS-acrylamide gels using antibodies against phosphorylated JKN1/2 (Cell Signaling), LEPR (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and SOCS1 (Abcam, Cambridge, MA, USA) respectively.

Statistical analysis

Values are expressed as mean $\pm$ S.E.M. All groups of animals were studied in parallel. Comparisons between different groups were performed by Student's *t*-test for unpaired samples. The level of significance was $P<0.05$.

Results

Mapping of the *Nmfl5* locus

To genetically map the *Nmfl5* mutation, mutant mice were outcrossed to the strain AKR/J and the F1 generation backcrossed to AKR/J to produce a mapping panel. Twelve-week body weight was used as a quantitative trait (Fig. 1A). We initially mapped the body weight trait to chromosome 5 with a suggestive LOD score of 2.25 (Fig. 1B). To confirm and refine the map position, a second BC cohort was analyzed using additional, more closely spaced markers on chromosome 5. The *Nmfl5* map position was confirmed with a peak LOD score of 13.8 on distal chromosome 5. The 95% confidence interval was between 44 and 60 cM (Fig. 1C).

B6-*Nmfl5*/+ mice are obese and have decreased activity levels and reduced oxygen consumption

Body weight and body composition from dominant obese B6-*Nmfl5*/+ mice were measured. The body weight changes in B6-+/+ and B6-*Nmfl5*/+ mice from 4 to 20 weeks of age are shown in Fig. 2A. At 12 weeks of age, B6-*Nmfl5*/+ mice are heavier than controls

Table 1 Clinical chemistry analyses of B6-*Nmfl5*/+ mice at 20–25 weeks age. Whole blood was collected via the orbital sinus using EDTA-coated capillary tubes. Samples were centrifuged and plasma was used for all biochemical assays. Data are mean $\pm$ S.E.M.

	B6-+/+	B6-+/Nmfl5	P value
Direct LDL cholesterol (mg/dl)	1.7 $\pm$ 0.4	6.7 $\pm$ 0.6	<0.002
Cholesterol (mg/dl)	62 $\pm$ 2.9	112 $\pm$ 11	<0.01
HDL cholesterol (mg/dl)	58 $\pm$ 1.6	115 $\pm$ 6	<0.004
Glucose (mg/dl)	184 $\pm$ 3.9	170 $\pm$ 9.8	NS
Thyroxine (T ₄ ; µg/dl)	2.9 $\pm$ 0.3	4.4 $\pm$ 0.5	<0.06
Triglyceride (mg/dl)	95 $\pm$ 7.5	143 $\pm$ 3.8	<0.03
Free fatty acids (mEq/l)	3.4 $\pm$ 0.3	4.72 $\pm$ 0.5	<0.05

NS, not significant.

Figure 4 B6-*Nmf15*/+ mice have impaired glucose metabolism. Longitudinal measurement of insulin (A), insulin tolerance test (ITT) (B), and glucose tolerance test (GTT) (C) in B6-*Nmf15*/+ mice. Data are mean $\pm$ S.E.M., ($n \geq 10$), * $P < 0.05$, ** $P < 0.01$ for B6-*Nmf15*/+ samples versus the respective B6-+/+ samples.

(female: 32 ± 4.6 vs 24 ± 1.8 ; male: 35 ± 3.5 vs 27 ± 2.5). This increase was exclusively due to an increase in body fat, since lean body mass was not different in B6-*Nmf15*/+ mice compared with their littermates at 12–14 week of age. The body fat gain of B6-*Nmf15*/+ mice was more than three times higher (15.2 g) than that of control mice (5.2 g; Fig. 2B and C).

B6-*Nmf15*/+ and control mice at 8 weeks of age (pre-obese) were housed in the CLAMS. All animals were single housed in the metabolic cages over a 5-day period for collection of data. Only the last 3-day period was analyzed to reduce variation introduced by adapting to a new environment. Figure 2 shows the daily patterns of metabolic measurements. Total locomotor activity was reduced (Fig. 2D), and the overall food intake was the same in B6-*Nmf15*/+ mice compared with littermate controls, indicating that B6-*Nmf15*/+ mice are not hyperphagic (Fig. 2E). There was decreased consumption of oxygen (Fig. 2F) during the darkness and light periods, perhaps reflecting the reduced activity levels. The respiratory quotient, indicative of macronutrient utilization, was not different between B6-*Nmf15*/+ mice and littermate controls (data not shown).

B6-Nmf15/+ mice are hyperleptinemic and show reduced leptin sensitivity in the hypothalamus

A panel of immunoassays for mouse adipokines was used to profile longitudinal changes in B6-*Nmf15*/+ mice between 8 and 32 weeks of age (Fig. 3A and B). Both female and male B6-*Nmf15*/+ mice at 8 weeks did not show a significant difference in body weight and body fat compared with their controls (Fig. 2A). However, leptin levels were already significantly elevated in young pre-obese B6-*Nmf15*/+ mice ($13\,560 \pm 4600$ vs 2300 ± 447 , $P < 0.005$; Fig. 3A). Circulating adiponectin levels in B6-*Nmf15*/+ mice were slightly higher than their controls at 8 and 16 weeks, but not different by 32 weeks of age (Fig. 3B). There was no difference in the levels of resistin between B6-*Nmf15*/+ mice and normal littermates (data not shown).

To assess whether the high leptin levels in *Nmf15* mice may be caused by leptin resistance, the hypothalamic protein levels of LEPR and SOCS1 were determined. Increased levels of Leptin receptor (2.5-fold) and SOCS1 (1.35-fold) were observed in *Nmf15* mice compared with their controls (Fig. 3C and D). We also measured STAT3 activation in the hypothalamus. In our study, STAT3 phosphorylation was increased 1.7-fold in control mice after leptin stimulation, but was not significantly increased in *Nmf15* mice (Fig. 3E).

B6-Nmf15 mice have impaired glucose metabolism

Table 1 shows baseline data for blood constituents in 20–25-week-old male B6-*Nmf15*/+ mice. No differences were detected in plasma glucose, but hyperinsulinemia was

Figure 5 Histology and ECG analysis of cardiomyopathy in obese *B6-Nmf15/+* mice. HE histological cross sections of hearts from 20- to 25-week-old *B6-Nmf15/+* mice (B), and their littermate controls (A). The arrows mark the thickened ventricular wall. Normal liver histology in *B6-+/+* (C). Nutmeg ‘speckled’ liver was observed in *B6-Nmf15/+* mice (D). The arrow marks the dark red areas of central venous congestion characteristic of ‘nutmeg’ liver. Measurements of blood pressure and heart rate (E) ($n=12$). Representative images from a total of $n\geq 10$ mice examined are shown.

observed in male *B6-Nmf15/+* mice from 16 weeks of age (Fig. 4A). There were elevated levels in triglyceride (143 ± 3.8 vs 95.3 ± 7.5 mg/dl, $P<0.03$) and free fatty acid (4.72 ± 0.5 vs 3.4 ± 0.3 mEq/l, $P<0.05$) between *B6-Nmf15/+* mice and normal littermates (Table 1). *Nmf15* mice exhibited impaired glucose tolerance (Fig. 4C), and these mice were unresponsive to exogenous insulin during an ITT (Fig. 4B), indicating marked insulin resistance.

B6-Nmf15/+ obese mice develop cardiomyopathy, renal lipidosis, and adipose tissue inflammation

B6-Nmf15/+ mice also demonstrate both histological and pathophysiological evidence of cardiomyopathy. Histological analysis revealed that hearts from 20-week-old *B6-Nmf15/+* mice displayed distinguishable chamber dilation and decreased thickness of the ventricular wall (Fig. 5B) in comparison with their controls (Fig. 5A). To characterize the disease phenotype, we conducted echocardiography to assess global cardiac function in *B6-Nmf15/+* mice in comparison with age-matched littermate controls. Echocardiography (echo) demonstrated that left ventricular ejection fraction (LV EF), left ventricular shortening (LV ES), and cardiac output were reduced and the LV cavity was dilated in *B6-Nmf15/+* mice at 20 weeks of age (Table 2). There was a tendency towards lower BP (106 ± 22 vs 95 ± 24 /mmHg) and a significant decrease in pulse rate (711 ± 15.7 vs 652 ± 13.9 , $P<0.05$ /beats per min) in *B6-Nmf15/+* mice at 12–16 weeks of age (Fig. 5E). Livers from *B6-Nmf15/+* animals exhibited a classical ‘nutmeg’ appearance with dark red areas of central venous congestion (Fig. 5D) compared to normal liver histology in *B6-+/+* mice (Fig. 5C). Long-standing chronic passive congestion of the liver is characterized by congested parenchyma around the central veins surrounded by paler peripheral tissue. Nutmeg liver is thought to be caused by chronic passive congestion of the liver secondary to heart failure (Kawase *et al.* 2002).

Lipid deposits have been observed in multiple tissues in obese *B6-Nmf15/+* mice. Kidney vacuolizations were found in *B6-Nmf15/+* mice at 20–25 weeks age. Vacuoles were present in proximal tubule epithelial cells and proteinaceous material accumulated in the tubules (Fig. 6B). Signs of glomerulosclerosis were also observed in the kidney of *B6-Nmf15/+* mice (Fig. 6B, D, and F). Frozen sections of the kidney from *B6-Nmf15/+* mice

Table 2 Echocardiography of *B6-Nmf15/+* cardiac function

	B6-+/+	B6-+/Nmf15	P value
BW* (g)	29±3.0	44±3.7	<0.01
IVS, d (mm)	0.85±0.04	0.78±0.04	NS
IVS, s (mm)	1.3±0.03	1.1±0.07	<0.05
LVID, d (mm)	3.9±0.38	4.2±0.48	NS
LVID, s (mm)	2.5±0.3	2.9±0.4	<0.05
CO/BW (ml/min per g)	0.7±0.03	0.4±0.05	<0.01
LV EF (%)	0.7±0.03	0.5±0.04	<0.05
LV ES (%)	0.4±0.02	0.3±0.03	<0.05

BW, body weight; IVS, d, interventricular septum thickness in diastole; IVS, s, interventricular septum thickness in systole; LVID, d, left ventricular inner dimension in diastole; LVID, s, left ventricular inner dimension in systole; CO/BW, cardiac output per body weight; LV EF, left ventricular ejection fraction; LV ES, left ventricular shortening. $P<0.05$ versus *B6-+/+* value ($n=8-10$).
*but not controls (C)

were strongly stained by Oil-Red-O for lipid in tubular epithelial cells (Fig. 6D) and in glomeruli (Fig. 6F). Staining for lipid on frozen sections from the littermate controls yielded negative results. The livers in both male and female B6-*Nmf15*^{+/+} mice were significantly larger than those of their littermate controls. The macro- and micro-vesicular lipid deposits using HE staining and Oil-Red-O frozen staining revealed remarkable hepatosteatosi in B6-*Nmf15*^{+/+} mice (Fig. 6H and J).

Adipose tissue from B6-*Nmf15*^{+/+} mice showed a remarkable degree of inflammation and macrophage infiltration. Histological analyses revealed mononuclear infiltrates in white adipose tissue from B6-*Nmf15*^{+/+} mice. The majority of infiltrating cells were macrophages (Fig. 7B and D), as *in situ* hybridization assays demonstrated that they expressed the macrophage-specific marker F4/80 (Fig. 7D). Activation of JNK (now called MAPK8)

has been associated with obesity-induced inflammation in adipose tissue (Solinas *et al.* 2007). We analyzed JNK1/2 phosphorylation in protein extracts from adipose tissue of B6-*Nmf15*^{+/+} mice and controls. As shown in Fig. 7E, JNK phosphorylation was enhanced twofold in B6-*Nmf15*^{+/+} mice compared with their controls. Furthermore, we measured the protein and phosphorylation levels of JNK in B6-*Nmf15*^{+/+} mice by western blotting. Phosphorylation of JNK in adipose tissue of B6-*Nmf15*^{+/+} mice was significantly increased compared with controls (Fig. 7F). Adipose tissue is an important endocrine organ producing various cytokines that are involved in inflammatory pathways, such as IL-6, TNF- α , MCP-1, and PAI-1 (Kershaw & Flier 2004). Adipose cytokine gene expression levels (IL-6, TNF- α , MCP-1, and PAI-1) in adipose tissue of B6-*Nmf15*^{+/+} mice were all significantly higher than in controls (Fig. 7G).

Figure 6 Renal and liver lipidosis in obese B6-*Nmf15*^{+/+} mice at 25 weeks of age. HE staining for kidney (A and B). Oil-Red-O staining for kidney (C, D, E, and F). Tubular compartment ($\times 100$) (C and D) and glomeruli ($\times 40$) (E and F) and HE staining for liver (G and H). Oil-Red-O staining for liver (I and J). Representative images from a total of four mice examined are shown.

Figure 7 Macrophage infiltration in adipose tissue of obese B6-*Nmf15*/+ mice at 25 weeks of age. HE staining of adipose tissue (A and B). F4/80-positive macrophages were detected with a F4/80 antisense riboprobe (C and D). Increased JNK1/2 phosphorylation in inflammatory adipose tissue (E and F). Adipose tissue cytokine gene expression by real-time PCR (G). Representative images from a total of three mice examined are shown. * $P < 0.05$, ** $P < 0.01$ for B6-*Nmf15*/+ samples versus the respective B6-+/+ samples.

Discussion

The MS is a cluster of metabolic abnormalities, including obesity, insulin resistance, and dyslipidemia, which individually and collectively are major risk factors for cardiovascular disease. More recently, it has been proposed that an inflammatory state induced by obesity may underlie many of these risk factors (Rana *et al.* 2007). Here, we describe a new mouse model of obesity, *Nmf15*, which combines several of the features and complications of human MS, including adipose tissue inflammation and cardiomyopathy.

A genome-wide scan using microsatellite markers was carried out and the *Nmf15* mutation was mapped to distal chromosome 5. No previously mapped genes in this area have been associated with obesity or leptin signaling. However, QTL affecting body weight in four different crosses have been mapped to the same region (Brockmann *et al.* 2000, Togawa *et al.* 2006). Potential candidate genes in the region include thyroid hormone receptor-associated protein 2 (*Med13l*), neuropeptide FF receptor 2 (*Npffr2*), G-coupled protein receptor 81 (*Gpr81*), and carbohydrate response element-binding protein (*Mlxip*). Analysis of the cDNA of these genes did not detect any sequence variation. The *Nmf15* locus in the distal region on mouse chromosome 5 shares conserved synteny with a region of human chromosome 7. Two studies have recently reported that a novel locus for autosomal-dominant cardiomyopathy maps to this region (Schonberger *et al.* 2005, Song *et al.* 2006). The *Nmf15* locus is, therefore, likely to encode a previously undescribed signal or factor essential for the development of obesity and cardiac failure in *Nmf15* mice, or defines a previously unknown function for a known gene.

Hotamisligil *et al.* (1993) have demonstrated the existence of an inflammatory state involving the adipose tissue for the first time in 1993. Adipocytes are the most important source of adiponectin. A strong epidemiological relationship between low circulating adiponectin and diabetes, MS, and cardiovascular disease has been reported in humans (Chandran *et al.* 2003, Fantuzzi 2005). B6-*Nmf15*/+ mice showed initially increased plasma adiponectin levels compared with controls, but the levels declined later in the development of the B6-*Nmf15*/+ obesity syndrome (Fig. 3B). Todoric *et al.* (2006) reported that high-fat diet-induced down-regulation of adiponectin gene expression in *Lepr^{db}* mice was paralleled by reduced adiponectin serum concentration. NONcNZO5, a polygenic obesity syndrome mouse strain, showed a tendency for first increased and then reduced serum adiponectin levels during aging and progression of the obesity phenotype (Leiter *et al.* 2007). Several reports have ascribed anti-inflammatory effects to adiponectin, including inhibition of TNF production and activity, inhibition of nuclear factor- κ B activation, induction of anti-inflammatory cytokines, as well as downregulation of adhesion molecules (Wolf *et al.* 2004, Yamaguchi *et al.* 2008). This indicates that adiponectin may be induced as a protective response to adipose tissue

inflammation. As the inflammation in B6-*Nmf15*/+ mice progresses, however, the protective mechanisms may become overwhelmed and adiponectin levels decline.

The finding that B6-*Nmf15*/+ mice are hyperleptinemic before the increase in adipose tissue mass suggests that leptin resistance underlies the observed phenotypes. This is supported by our finding that the downstream intermediate of the leptin-signaling pathway, STAT3, is not phosphorylated in the hypothalamus in response to leptin stimulation in *Nmf15* mice as it is in control B6 mice. Obese rodents, and humans, are resistant to leptin, in some cases because of genetic disposition (primary resistance), but commonly in response to high leptin levels (secondary resistance; Arch 2005). In the latter cases, it is likely that an extended period of exposure of the brain, especially the hypothalamus, to a high level of leptin may result in the development of central leptin resistance and unsuppressed insulin secretion. Leptin resistance in peripheral tissues also has a role in the development of co-morbidities in obesity (Banks 2008). The leptin resistance observed in B6-*Nmf15*/+ mice suggests that leptin signaling does not function properly. The brain may not receive messages (defect in leptin transport) or may be unable to relay signals to the peripheral metabolic organ systems (impaired signaling pathways).

B6-*Nmf15*/+ mice are leptin resistant, but maintain a normal food intake. Therefore, the obese phenotype of B6-*Nmf15*/+ mice is not caused by hyperphagia as in *Lep^{db}* mice, but rather by altered effects of leptin on energy expenditure in the periphery or in the brain. Our observation that B6-*Nmf15*/+ mice show reduced locomotor activity in the metabolic cages supports that notion.

Plasma enzyme activities indicated that B6-*Nmf15*/+ mice experience some stress on organs leading to tissue damage. This was confirmed by histology showing abnormalities in pancreas, kidney, heart, and the liver. The pancreatic islet hyperplasia is consistent with the hyperinsulinemia observed in male B6-*Nmf15*/+ mice. Plasma glucose levels, however, were not different in B6-*Nmf15*/+ mice compared with controls. It is commonly observed that obesity mutations on a B6 genetic background do not lead to the development of diabetes, whereas the same mutations on a diabetogenic background, such as C57BLKS, will produce hyperglycemia. This presumably reflects the presence of deleterious alleles in some mouse strains promoting decompensation of pancreatic β -cells.

Kimmelstiel & Wilson (1936) demonstrated the presence of lipid deposits in the kidneys of diabetic patients, and they suggested that these lipids play an important role in the pathogenesis of renal disease. Since then, several investigators have shown the accumulation of lipids in the kidneys of diabetic humans and experimental animals (Moorhead *et al.* 1982, Ruan *et al.* 2004, Proctor *et al.* 2006). Our finding of early signs of glomerulosclerosis and lipid deposits in the kidneys of a normoglycemic model of MS may indicate that insulin and/or leptin resistance in MS already set up pathological changes that are then

exacerbated by the high glucose levels in diabetes to progress to diabetic nephropathy.

Our finding of DCM in the hyperleptinemic B6-*Nmf15*/+ mice is intriguing. Bradycardia and PR interval lengthening as in *Nmf15* mice have been observed in human obese patients (Frank *et al.* 1986) and DCM is frequently associated with ECG abnormalities. The effects of the adipocyte-derived hormone leptin on the cardiovascular system have recently attracted more attention (Soderberg *et al.* 1999, 2003), and there is growing interest in the cardiovascular activity of the leptin-signaling pathway (Yamagishi *et al.* 2001). Expression of several isoforms of the leptin receptor (both long and short) has been demonstrated in the myocardium and in isolated myocytes (Aasum *et al.* 2003) suggesting specific effects of leptin in the heart. Altered levels of leptin and its receptor have been described in patients with chronic heart failure (Garg & Yusuf 1993, Patterson & Adams 1996). Several studies have shown a correlation between hyperleptinemia and cardiac hypertrophy (Buckingham *et al.* 2005), and increased leptin levels correlate with myocardial wall dysfunction (Abel *et al.* 2008, He *et al.* 2008).

Mice with mutations in the leptin receptor have been shown to develop cardiomyopathy (Yue *et al.* 2007) indicating that leptin resistance can contribute to diabetic myocardial disease. Conversely, leptin has been shown to exert protective effects against lipotoxic cardiomyopathy (Lee *et al.* 2004).

It remains an open question whether cardiomyopathy in obesity is due to hyperleptinemia or to leptin resistance. On the one hand, many epidemiological and biochemical studies associate hyperleptinemia with cardiomyopathy. On the other hand, cardiomyopathy in *Lep^{db}* mice arises from leptin deficiency and can be reversed by leptin treatment, indirectly implicating leptin resistance in human obesity-associated cardiomyopathy. In the special case of the *Nmf15* mutant mice, it remains possible that direct effects of the mutated gene in cardiac tissue lead to cardiomyopathy.

Our characterization of the *Nmf15* mice shows that this novel model for MS will be useful for studying leptin resistance and the etiology of leptin resistance-associated cardiomyopathy, and will contribute to a better understanding of the molecular causes of this recently recognized complication of MS.

Declaration of interest

There is no conflict of interest among authors that would prejudice the impartiality of this work.

Funding

This work was supported by National Institute of Diabetes, Digestive, and Kidney Diseases Grant (DK46977). The Jackson Laboratory core services were supported by an institutional grant (CA-24190).

References

- Aasum E, Hafstad AD, Severson DL & Larsen TS 2003 Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. *Diabetes* **52** 434–441.
- Abel ED, Litwin SE & Sweeney G 2008 Cardiac remodeling in obesity. *Physiological Reviews* **88** 389–419.
- Arch JR 2005 Central regulation of energy balance: inputs, outputs and leptin resistance. *Proceedings of the Nutrition Society* **64** 39–46.
- Banks WA 2008 The blood–brain barrier as a cause of obesity. *Current Pharmaceutical Design* **14** 1606–1614.
- Brockmann GA, Kratzsch J, Haley CS, Renne U, Schwerin M & Karle S 2000 Single QTL effects, epistasis, and pleiotropy account for two-thirds of the phenotypic F(2) variance of growth and obesity in DU6i×DBA/2 mice. *Genome Research* **10** 1941–1957.
- Broman KW, Wu H, Sen S & Churchill GA 2003 R/qtl: QTL, mapping in experimental crosses. *Bioinformatics* **19** 889–890.
- Buckingham M, Meilhac S & Zaffran S 2005 Building the mammalian heart from two sources of myocardial cells. *Nature Reviews. Genetics* **6** 826–835.
- Cancello R & Clement K 2006 Is obesity an inflammatory illness? Role of low-grade inflammation and macrophage infiltration in human white adipose tissue. *British Journal of Obstetrics and Gynaecology* **113** 1141–1147.
- Chandran M, Phillips SA, Ciaraldi T & Henry RR 2003 Adiponectin: more than just another fat cell hormone? *Diabetes Care* **26** 2442–2450.
- Churchill GA & Doerge RW 1994 Empirical threshold values for quantitative trait mapping. *Genetics* **138** 963–971.
- Coleman DL 1985 Increased metabolic efficiency in obese mutant mice. *International Journal of Obesity* **9** 69–73.
- Eckel RH, Grundy SM & Zimmet PZ 2005 The metabolic syndrome. *Lancet* **365** 1415–1428.
- Fantuzzi G 2005 Adipose tissue, adipokines, and inflammation. *Journal of Allergy and Clinical Immunology* **115** 911–919 (quiz 920).
- Fein FS 1990 Diabetic cardiomyopathy. *Diabetes Care* **13** 1169–1179.
- Ford ES, Giles WH & Dietz WH 2002 Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *Journal of the American Medical Association* **287** 356–359.
- Frank S, Collier JA & Frank A 1986 The electrocardiogram in obesity: statistical analysis of 1,029 patients. *Journal of the American College of Cardiology* **7** 295–299.
- Garg R & Yusuf S 1993 Current and ongoing randomized trials in heart failure and left ventricular dysfunction. *Journal of the American College of Cardiology* **22** 194A–197A.
- Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr & Sowers JR 1999 Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation* **100** 1134–1146.
- He H, Shi M, Zeng X, Yang J, Li Y, Wu L & Li L 2008 Cardioprotective effect of salvianolic acid B on large myocardial infarction mediated by reversing upregulation of leptin, endothelin pathways, and abnormal expression of SERCA2a, phospholamban in rats. *Journal of Ethnopharmacology* **118** 35–45.
- Heilbronn LK & Campbell LV 2008 Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. *Current Pharmaceutical Design* **14** 1225–1230.
- Hotamisligil GS, Shargill NS & Spiegelman BM 1993 Adipose expression of tumor necrosis factor- α : direct role in obesity-linked insulin resistance. *Science* **259** 87–91.
- Kawase Y, Takemura G, Hayakawa K, Koda M, Maruyama R, Kanoh M, Kunishima A, Arai M, Minatoguchi S, Ohkusa T *et al.* 2002 Abundant apoptosis in nutmeg liver of cardiomyopathic hamsters. Apoptotic cell death as a possible mechanism of hepatic remodeling by congestion. *Pathology, Research and Practice* **198** 291–298.
- Kershaw EE & Flier JS 2004 Adipose tissue as an endocrine organ. *Journal of Clinical Endocrinology and Metabolism* **89** 2548–2556.
- Kimmelstiel P & Wilson C 1936 Intercapillary lesions in the glomeruli of the kidney. *American Journal of Pathology* **12** 83–98.
- Lee Y, Naseem RH, Duplomb L, Park BH, Garry DJ, Richardson JA, Schaffer JE & Unger RH 2004 Hyperleptinemia prevents lipotoxic cardiomyopathy in acyl CoA synthase transgenic mice. *PNAS* **101** 13624–13629.
- Leiter EH, Reifsnnyder PC, Xiao Q & Mistry J 2007 Adipokine and insulin profiles distinguish diabetogenic and non-diabetogenic obesities in mice. *Obesity* **15** 1961–1968.
- Martin TL, Alquier T, Asakura K, Furukawa N, Preitner F & Kahn BB 2006 Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. *Journal of Biological Chemistry* **281** 18933–18941.
- Moorhead JF, Chan MK, El-Nahas M & Varghese Z 1982 Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. *Lancet* **2** 1309–1311.
- Munzberg H, Flier JS & Bjorbaek C 2004 Region-specific leptin resistance within the hypothalamus of diet-induced obese mice. *Endocrinology* **145** 4880–4889.
- Olufadi R & Byrne CD 2008 Clinical and laboratory diagnosis of the metabolic syndrome. *Journal of Clinical Pathology* **61** 697–706.
- Patterson JH & Adams KF Jr 1996 Pathophysiology of heart failure: changing perceptions. *Pharmacotherapy* **16** 27S–36S.
- Proctor G, Jiang T, Iwahashi M, Wang Z, Li J & Levi M 2006 Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. *Diabetes* **55** 2502–2509.
- Rana JS, Nieuwdorp M, Jukema JW & Kastelein JJ 2007 Cardiovascular – metabolic syndrome – an interplay of, obesity, inflammation, diabetes and coronary heart disease. *Diabetes, Obesity and Metabolism* **9** 218–232.
- Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH & Varghese Z 2004 Regulation of lipoprotein trafficking in the kidney: role of inflammatory mediators and transcription factors. *Biochemical Society Transactions* **32** 88–91.
- Schonberger J, Kuhler L, Martins E, Lindner TH, Silva-Cardoso J & Zimmer M 2005 A novel locus for autosomal-dominant dilated cardiomyopathy maps to chromosome 7q22.3–31.1. *Human Genetics* **118** 451–457.
- Soderberg S, Ahren B, Jansson JH, Johnson O, Hallmans G, Asplund K & Olsson T 1999 Leptin is associated with increased risk of myocardial infarction. *Journal of Internal Medicine* **246** 409–418.
- Soderberg S, Stegmayr B, Ahlbeck-Glader C, Slunga-Birgander L, Ahren B & Olsson T 2003 High leptin levels are associated with stroke. *Cerebrovascular Diseases* **15** 63–69.
- Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, Grivennikov S, Wynshaw-Boris A, Scadeng M, Olefsky JM *et al.* 2007 JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. *Cell Metabolism* **6** 386–397.
- Song L, DePalma SR, Kharlap M, Zenovich AG, Cirino A, Mitchell R, McDonough B, Maron BJ, Seidman CE, Seidman JG *et al.* 2006 Novel locus for an inherited cardiomyopathy maps to chromosome 7. *Circulation* **113** 2186–2192.
- Tiffin N, Okpechi I, Perez-Iratxeta C, Andrade-Navarro MA & Ramesar R 2008 Prioritisation of candidate disease genes for metabolic syndrome by computational analysis of its defining phenotypes. *Physiological Genomics* **35** 55–64.
- Todoric J, Loffler M, Huber J, Bilban M, Reimers M, Kadl A, Zeyda M, Waldhausl W & Stulnig TM 2006 Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. *Diabetologia* **49** 2109–2119.
- Togawa K, Moritani M, Yaguchi H & Itakura M 2006 Multidimensional genome scans identify the combinations of genetic loci linked to diabetes-related phenotypes in mice. *Human Molecular Genetics* **15** 113–128.
- Tomlinson KC, Gardiner SM, Hebden RA & Bennett T 1992 Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. *Pharmacological Reviews* **44** 103–150.
- Wang Y, Nose M, Kamoto T, Nishimura M & Hiai H 1997 Host modifier genes affect mouse autoimmunity induced by the *lpr* gene. *American Journal of Pathology* **151** 1791–1798.
- Wang Y, Seburn K, Bechtel L, Lee BY, Szatkiewicz JP, Nishina PM & Naggert JK 2006 Defective carbohydrate metabolism in mice homozygous for the tubby mutation. *Physiological Genomics* **27** 131–140.

- Wellen KE & Hotamisligil GS 2003 Obesity-induced inflammatory changes in adipose tissue. *Journal of Clinical Investigation* **112** 1785–1788.
- Wolf AM, Wolf D, Rumpold H, Enrich B & Tilg H 2004 Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. *Biochemical and Biophysical Research Communications* **323** 630–635.
- Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M & Brownlee M 2001 Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. *Journal of Biological Chemistry* **276** 25096–25100.
- Yamaguchi N, Kukita T, Li YJ, Kamio N, Fukumoto S, Nonaka K, Ninomiya Y, Hanazawa S & Yamashita Y 2008 Adiponectin inhibits induction of TNF- α /RANKL-stimulated NFATc1 via the AMPK signaling. *FEBS Letters* **582** 451–456.
- Yu Z, Quamme GA & McNeill JH 1994 Depressed $[Ca^{2+}]_i$ responses to isoproterenol and cAMP in isolated cardiomyocytes from experimental diabetic rats. *American Journal of Physiology* **266** H2334–H2342.
- Yue P, Arai T, Terashima M, Sheikh AY, Cao F, Charo D, Hoyt G, Robbins RC, Ashley EA, Wu J *et al.* 2007 Magnetic resonance imaging of progressive cardiomyopathic changes in the db/db mouse. *American Journal of Physiology. Heart and Circulatory Physiology* **292** H2106–H2118.

Received in final form 23 April 2009

Accepted 24 April 2009

Made available online as an Accepted Preprint
24 April 2009